Public consultation on interim decisions to amend the Poisons Standard - ACMS/ACCS & Joint meetings MARCH 2022

Closed 16 Sep 2022

Opened 19 Aug 2022

Overview

Scheduling amendments referred to expert advisory committee

This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the 15-16th March 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).

The closing date for this consultation is close of business 16 September 2022. All submissions received by the deadline will be considered by the delegate before they make a final decision.

The interim decisions under consultation are detailed in the public notice of interim decisions of March 2022.

Substances for which public comment is sought

  • Item 2.1 - Azelastine and fluticasone propionate
  • Item 3.1 - Cannabis and tetrahydrocannabinols
  • Item 3.2 - Lead
  • Item 3.3 - Meloxicam
  • Item 3.4 - Lidocaine 
  • Item 4.1 - Flumioxazin (both applications combined) 

What happens next

All public submissions will be published on the TGA website at Public submissions on scheduling matters, unless marked confidential or indicated otherwise in the submission information (see Privacy and your Personal information).

Public submissions are an important part of the process for amending the Poison Standard, and are published on the TGA website using the consultation hub.  Submissions by the public may not reflect the views of the Department of Health or TGA.  Published submissions should not be taken as being endorsed by the Department or TGA.

Following consideration of public submissions received before the closing date and advice from the expert advisory committees, decisions on the proposed amendments are anticipated to be published as final decisions on the TGA website: Scheduling delegate's final decisions  in October 2022.

Audiences

  • Anyone from any background

Interests

  • Hospitals
  • e-Health
  • Health technology
  • Medicare
  • Legislation
  • Pharmaceutical benefits
  • Health insurance
  • Rural health services
  • Regulatory policy
  • Women's health
  • Children's health
  • Learning and development
  • Dementia
  • Home Care
  • Aged Care
  • Residential Aged Care
  • Short-Term Restorative Care
  • Alcohol
  • Tobacco
  • Chronic disease
  • Communicable diseases
  • Mental health
  • Drugs and substance abuse
  • Food standards
  • Organ and tissue donation
  • Immunisation
  • Hearing
  • Aboriginal and Torres Strait Islander health
  • Environmental health
  • Prescription drugs
  • Preventative health
  • Dental health
  • Non-prescription medicines
  • Grants and procurement
  • Management review
  • Administration
  • Staff audit
  • Staff election
  • Disability Workforce Action Plan 2016-18
  • Capability
  • Information Technology
  • Strategic Policy
  • Policy Development
  • Cancer